

INTRODUCTION .....	XIII
STUDY GOALS AND OBJECTIVES.....	XIII
REASONS FOR DOING THE STUDY .....	XIII
SCOPE AND FORMAT .....	XIII
METHODOLOGY .....	XIV
RELATED BCC PUBLICATIONS .....	XIV
ANALYST CREDENTIALS.....	XV
BCC ONLINE SERVICES.....	XV
DISCLAIMER .....	XVI
 SUMMARY.....	 XVII
PRESCRIPTION OPHTHALMIC DRUGS: MAJOR MARKETS .....	XVII
<i>SUMMARY TABLE TOTAL U.S. MARKET FOR PRESCRIPTION OPHTHALMIC</i>	
<i>DRUGS, TOP THREE MAJOR MARKETS, AND REVENUES, THROUGH 2007 (\$</i>	
<i>MILLIONS)</i> .....	XVII
<i>SUMMARY FIGURE TOTAL U.S. MARKET FOR PRESCRIPTION OPHTHALMIC</i>	
<i>DRUGS, BY PRODUCT TYPE 2000-2007 (\$ MILLIONS)</i> .....	XVIII
LEADING PRODUCTS AND MANUFACTURERS .....	XVIII
 INDUSTRY OVERVIEW.....	 1
OPHTHALMIC DRUG INDUSTRY STRUCTURE.....	1
HISTORY AND GROWTH OF THE OPHTHALMIC DRUG	
MARKET .....	1
VISION OVERVIEW.....	2
Eye Structure.....	2
Eye Structure (Continued) .....	3
Vision Pathology .....	4
ISSUES, TRENDS AND DEMOGRAPHICS .....	5
DEMOGRAPHICS.....	5
Demographics (Continued).....	6
Demographics (Continued).....	7
<i>TABLE 1 U.S. INCIDENCE AND PREVALENCE OF SELECTED EYE CONDITIONS</i>	
<i>AND DISEASES</i> .....	8
<i>FIGURE 1 U.S. INCIDENCE AND PREVALENCE OF SELECTED EYE</i>	
<i>CONDITIONS AND DISEASES</i> .....	8
TRENDS AFFECTING THE MARKET .....	9
Medicare Coverage for Age-related Macular Degeneration	
Treatment.....	9
Medicare Appeals Process for Ophthalmology .....	10
INTRAOCULAR DRUG DELIVERY .....	11
The Elderly .....	12
Generic Competition.....	13
Advertising.....	14
<i>TABLE 2 TOP ADVERTISED OPHTHALMIC PHARMACEUTICAL PRODUCTS BY</i>	
<i>MARKETER</i> .....	14
Global Markets .....	15

EYE DISEASES AND THEIR TREATMENTS .....	16
CATARACT TREATMENTS .....	16
OVERVIEW .....	16
Product Description .....	17
Non-steroidal Anti-inflammatories .....	17
<i>TABLE 3 PRODUCT SUMMARY OF CATARACT TREATMENTS BY MANUFACTURER, PRODUCT TYPE AND FDA APPROVAL DATE</i> .....	17
Research and Development .....	17
<i>TABLE 4 PRODUCTS IN DEVELOPMENT FOR CATARACT TREATMENT BY MANUFACTURER AND DEVELOPMENT PHASE</i> .....	18
Market Size and Growth .....	18
<i>TABLE 5 MARKET REVENUES FOR CATARACT TREATMENTS BY PRODUCT TYPE, THROUGH 2007 (\$ MILLIONS)</i> .....	19
<i>FIGURE 2 MARKET FOR CATARACT TREATMENTS BY PRODUCT TYPE, 2000-2007 (\$ MILLIONS)</i> .....	19
Competitive Structure and Market Share .....	19
<i>TABLE 6 COMPETITIVE MARKET SHARES FOR CATARACT TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS)</i> .....	20
<i>FIGURE 3 COMPETITIVE MARKET SHARES FOR CATARACT TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (%)</i> .....	20
GLAUCOMA TREATMENTS .....	20
OVERVIEW .....	20
Overview (Continued) .....	21
Product Description .....	22
Beta-adrenergic Blockers .....	22
Carbonic Anhydrase Inhibitors .....	23
Miotics .....	24
Prostaglandins .....	25
Other Glaucoma Treatments .....	26
<i>TABLE 7 SUMMARY OF SELECTED GLAUCOMA TREATMENTS BY MANUFACTURER, PRODUCT TYPE AND FDA APPROVAL DATE</i> .....	27
Research and Development .....	28
<i>TABLE 8 PRODUCTS IN DEVELOPMENT FOR GLAUCOMA TREATMENT BY MANUFACTURER AND DEVELOPMENT PHASE</i> .....	28
Market Size and Growth .....	28
Market Size and Growth (Continued) .....	29
<i>TABLE 9 GLAUCOMA TREATMENT MARKET BY PRODUCT TYPE, THROUGH 2007 (\$ MILLIONS)</i> .....	30
<i>FIGURE 4 GLAUCOMA TREATMENT MARKET BY PRODUCT TYPE, 2000-2007 (\$ MILLIONS)</i> .....	30
Competitive Structure and Market Share .....	31
<i>TABLE 10 COMPETITIVE MARKET SHARE FOR GLAUCOMA TREATMENTS ACCORDING TO MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS)</i> .....	31
<i>FIGURE 5 COMPETITIVE MARKET SHARE FOR GLAUCOMA TREATMENTS ACCORDING TO MANUFACTURERS REVENUES, 2002 (%)</i> .....	32
OCULAR ALLERGY TREATMENTS .....	32
OVERVIEW .....	32
Product Description .....	33

Antihistamines.....	33
Mast Cell Stabilizers .....	33
Nonsteroidal Anti-Inflammatories.....	33
Vasoconstrictors.....	34
Other Ocular Allergy Treatments.....	34
<i>TABLE 11 SELECTED OCULAR ALLERGY TREATMENTS BY MANUFACTURER, PRODUCT TYPE AND FDA APPROVAL DATE .....</i>	<i>35</i>
Research and Development.....	35
<i>TABLE 12 PRODUCTS IN DEVELOPMENT FOR OCULAR ALLERGIES BY MANUFACTURER AND DEVELOPMENT PHASE .....</i>	<i>36</i>
Market Size and Growth .....	36
<i>TABLE 13 MARKETS FOR OCULAR ALLERGY TREATMENTS BY PRODUCT TYPE, THROUGH 2007 (\$ MILLIONS) .....</i>	<i>37</i>
<i>FIGURE 6 MARKETS FOR OCULAR ALLERGY TREATMENTS BY PRODUCT TYPE, 2000-2007 (\$ MILLIONS).....</i>	<i>37</i>
Competitive Structure and Market Share.....	38
<i>TABLE 14 COMPETITIVE MARKET SHARES FOR OCULAR ALLERGY TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS).....</i>	<i>38</i>
<i>FIGURE 7 COMPETITIVE MARKET SHARES FOR OCULAR ALLERGY TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (%) .....</i>	<i>39</i>
OCULAR INFECTION TREATMENTS .....	39
OVERVIEW .....	39
Hordeolum.....	39
Blepharitis.....	40
Conjunctivitis .....	40
Keratitis .....	41
CMV Retinitis .....	42
Product Descriptions .....	42
Antibiotics .....	42
Antibiotics (Continued).....	43
Antifungals.....	44
Antivirals.....	44
<i>TABLE 15 SUMMARY OF OCULAR INFECTION TREATMENTS BY MANUFACTURER, PRODUCT TYPE, AND FDA APPROVAL DATE .....</i>	<i>45</i>
Research and Development.....	45
<i>TABLE 16 PRODUCTS IN DEVELOPMENT FOR OCULAR INFECTIONS BY MANUFACTURER AND DEVELOPMENT PHASE .....</i>	<i>46</i>
Market Size and Growth .....	46
<i>TABLE 17 MARKET FOR OCULAR INFECTION TREATMENTS BY PRODUCT TYPE, THROUGH 2007 (\$ MILLIONS) .....</i>	<i>47</i>
<i>FIGURE 8 MARKETS FOR OCULAR INFECTION TREATMENTS BY PRODUCT TYPE, 2000-2007 (\$ MILLIONS).....</i>	<i>48</i>
Competitive Structure and Market Share.....	48
<i>TABLE 18 COMPETITIVE MARKET SHARES OF OCULAR INFECTION TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS).....</i>	<i>49</i>
<i>FIGURE 9 COMPETITIVE MARKET SHARES OF OCULAR INFECTION TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (%) .....</i>	<i>49</i>
OCULAR INFLAMMATION TREATMENTS .....	50

OVERVIEW .....	50
Chalazion .....	50
Inflammatory Conjunctivitis.....	50
Product Description .....	50
Corticosteroids .....	50
Corticosteroids (Continued) .....	51
Nonsteroidal Anti-inflammatories .....	52
TABLE 19 SUMMARY OF OCULAR INFLAMMATION TREATMENTS BY MANUFACTURER, PRODUCT TYPE AND FDA APPROVAL DATE .....	52
Research and Development.....	52
Market Size and Growth .....	53
TABLE 20 OCULAR INFLAMMATION TREATMENT MARKETS BY PRODUCT TYPE, THROUGH 2007 (\$ MILLIONS) .....	54
FIGURE 10 OCULAR INFLAMMATION TREATMENT MARKETS BY PRODUCT TYPE, 2000-2007 (\$ MILLIONS).....	54
Competitive Structure and Market Share.....	54
TABLE 21 COMPETITIVE MARKET SHARE OF OCULAR INFLAMMATION TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS).....	55
FIGURE 11 COMPETITIVE MARKET SHARE OF OCULAR INFLAMMATION TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (%) .....	55
RETINAL DISORDER TREATMENTS.....	56
OVERVIEW .....	56
Diabetic Retinopathy.....	56
Retinal Detachment.....	57
Age-related Macular Degeneration.....	57
Product Descriptions .....	58
Ocular Anesthetics.....	58
Other Treatments .....	58
TABLE 22 SUMMARY OF SELECTED RETINAL DISORDER TREATMENTS BY MANUFACTURER, PRODUCT TYPE, AND FDA APPROVAL DATE .....	59
Research and Development.....	59
Research and Development (Continued) .....	60
Research and Development (Continued) .....	61
Research and Development (Continued) .....	62
TABLE 23 PRODUCTS IN DEVELOPMENT FOR RETINAL DISORDERS BY MANUFACTURER AND DEVELOPMENT PHASE .....	63
Market Size and Growth .....	63
TABLE 24 MARKETS FOR RETINAL DISORDER TREATMENT PRODUCTS, THROUGH 2007 (\$ MILLIONS) .....	64
FIGURE 12 MARKETS FOR RETINAL DISORDER TREATMENT PRODUCTS, 2000- 2007 (\$ MILLIONS).....	64
Competitive Structure and Market Share.....	65
TABLE 25 COMPETITIVE MARKET SHARE OF RETINAL DISORDER TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS).....	65
FIGURE 13 COMPETITIVE MARKET SHARE OF RETINAL DISORDER TREATMENTS BY MANUFACTURER'S REVENUES, 2002 (%) .....	65
OTHER OCULAR TREATMENTS .....	66
OVERVIEW .....	66

Dry Eye Syndrome.....	66
Mydriasis .....	66
Ocular Muscle Spasms .....	66
Product Description .....	67
Mydriatics and Cycloplegics .....	67
Mydriatics and Cycloplegics (Continued) .....	68
PAIN MANAGEMENT TREATMENTS .....	69
Dry-eye Treatments.....	69
Ocular Muscle Spasm Treatments.....	70
TABLE 26 SUMMARY OF SELECTED OTHER OCULAR TREATMENT PRODUCTS BY MANUFACTURER, TYPE AND FDA APPROVAL DATE.....	71
Research and Development.....	71
TABLE 27 PRODUCTS IN DEVELOPMENT FOR OTHER OCULAR DISORDERS BY MANUFACTURER AND DEVELOPMENT PHASE .....	72
Market Size and Growth .....	73
TABLE 28 MARKETS FOR OTHER OCULAR TREATMENTS BY PRODUCT TYPE, THROUGH 2007 (\$ MILLIONS) .....	74
FIGURE 14 MARKETS FOR OTHER OCULAR TREATMENTS BY PRODUCT TYPE, 2000-2007 (\$ MILLIONS).....	74
Competitive Structure and Market Share.....	75
TABLE 29 COMPETITIVE MARKET SHARES OF OTHER OCULAR TREATMENT PRODUCTS BY MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS) .....	75
FIGURE 15 COMPETITIVE MARKET SHARES OF OTHER OCULAR TREATMENT PRODUCTS BY MANUFACTURER'S REVENUES, 2002 (\$ MILLIONS) .....	75
MARKET AND TECHNOLOGY SUMMARY .....	76
TOTAL MARKET FOR PRESCRIPTION OPHTHALMIC DRUGS .....	76
TABLE 30 TOTAL U.S. MARKET FOR PRESCRIPTION OPHTHALMIC DRUGS, THROUGH 2007 (\$ MILLIONS) .....	76
FIGURE 16 TOTAL U.S. MARKET FOR PRESCRIPTION OPHTHALMIC DRUGS BY PRODUCT TYPE, 2000-2007 (\$ MILLIONS).....	77
TOTAL MARKET PERCENT DISTRIBUTION BY PRODUCT TYPE .....	77
TABLE 31 TOTAL U.S. PRESCRIPTION OPHTHALMIC DRUG MARKET DISTRIBUTION BY PRODUCT TYPE, THROUGH 2007 (%).....	78
FIGURE 17 TOTAL U.S. PRESCRIPTION OPHTHALMIC DRUG MARKET DISTRIBUTION BY PRODUCT TYPE, 2000-2007 (%).....	78
INDUSTRY PARTICIPANTS AND COMPETITOR ANALYSIS .....	79
TABLE 32 INDUSTRY PARTICIPANTS BY PRODUCT TYPE, 2002 .....	79
FIGURE 18 INDUSTRY PARTICIPATION BY NUMBER OF MANUFACTURERS IN EACH TREATMENT SEGMENT (NUMBER OF MANUFACTURERS) .....	80
FIGURE 19 DISTRIBUTION OF INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT (PERCENT OF MANUFACTURERS) .....	80
TABLE 33 LIST OF SELECTED FDA APPROVED PRESCRIPTION OPHTHALMIC DRUGS BY MANUFACTURER .....	81
TECHNOLOGY.....	82
OVERVIEW .....	82
CURRENT TECHNOLOGY USES.....	82
PATENT EVALUATION BY DRUG .....	83

TABLE 34 U.S. PATENT AND EXCLUSIVITY INFORMATION BY DRUG* FOR SELECTED PRESCRIPTION OPHTHALMIC PHARMACEUTICALS .....	83
TABLE 34 (CONTINUED).....	84
TABLE 34 (CONTINUED).....	85
TABLE 34 (CONTINUED).....	86
NEW TECHNOLOGY DEVELOPMENTS .....	86
New Technology Developments (Continued).....	87
COMPANY PROFILES .....	88
ALCON LABORATORIES, INC.....	88
ALLERGAN, INC.....	88
BAUSCH & LOMB, INC.....	89
FALCON PHARMACEUTICALS, LTD. ....	89
HOFFMANN LAROCHE, INC.....	90
MEDIMMUNE, INC. ....	90
MERCK & COMPANY, INC.....	90
NOVARTIS OPHTHALMICS, INC.....	91
PHARMACIA CORP.....	91
WYETH .....	92
APPENDIX I.....	93
LEADING DRUG MANUFACTURERS .....	93
FIGURE 20 COMPANIES AND RELATED ORGANIZATIONS IN THE U.S. MARKET FOR PRESCRIPTION OPHTHALMIC DRUGS (NUMBER OF PARTICIPANTS).....	93
LEADING DRUG MANUFACTURERS (CONTINUED).....	94
LEADING DRUG MANUFACTURERS (CONTINUED).....	95
LEADING DRUG MANUFACTURERS (CONTINUED).....	96
LEADING DRUG MANUFACTURERS (CONTINUED).....	97
APPENDIX II.....	98
OTHER MANUFACTURERS AND COMPANIES .....	98
OTHER MANUFACTURERS AND COMPANIES (CONTINUED).....	99
OTHER MANUFACTURERS AND COMPANIES (CONTINUED).....	100
OTHER MANUFACTURERS AND COMPANIES (CONTINUED).....	101
APPENDIX III .....	102
ASSOCIATIONS, ORGANIZATIONS AND UNIVERSITIES .....	102
ASSOCIATIONS, ORGANIZATIONS AND UNIVERSITIES (CONTINUED).....	103